148 related articles for article (PubMed ID: 2696394)
21. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer.
Royer B; Delroeux D; Guardiola E; Combe M; Hoizey G; Montange D; Kantelip JP; Chauffert B; Heyd B; Pivot X
Cancer Chemother Pharmacol; 2008 Mar; 61(3):415-21. PubMed ID: 17503047
[TBL] [Abstract][Full Text] [Related]
22. Presence of cancerostatic platinum compounds in hospital wastewater and possible elimination by adsorption to activated sludge.
Lenz K; Hann S; Koellensperger G; Stefanka Z; Stingeder G; Weissenbacher N; Mahnik SN; Fuerhacker M
Sci Total Environ; 2005 Jun; 345(1-3):141-52. PubMed ID: 15919535
[TBL] [Abstract][Full Text] [Related]
23. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
24. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
25. Comparative clinical pharmacology of cisplatin and carboplatin.
Murry DJ
Pharmacotherapy; 1997; 17(5 Pt 2):140S-145S. PubMed ID: 9322881
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of carboplatin (CBDCA) in children with cancer.
Bacha DM; Caparros-Sison B; Allen JA; Walker R; Tan CT
Cancer Treat Rep; 1986 Jul; 70(7):865-9. PubMed ID: 3521846
[TBL] [Abstract][Full Text] [Related]
27. The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research.
Brouwers EE; Tibben M; Rosing H; Schellens JH; Beijnen JH
Mass Spectrom Rev; 2008; 27(2):67-100. PubMed ID: 18231971
[TBL] [Abstract][Full Text] [Related]
28. Use of a toxicity factor to explain differences in nephrotoxicity and myelosuppression among the platinum antitumour derivatives cisplatin, carboplatin and nedaplatin in rats.
Hanada K; Asano K; Nishimura T; Chimata T; Matsuo Y; Tsuchiya M; Ogata H
J Pharm Pharmacol; 2008 Mar; 60(3):317-22. PubMed ID: 18284811
[TBL] [Abstract][Full Text] [Related]
29. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
Rice JR; Gerberich JL; Nowotnik DP; Howell SB
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
[TBL] [Abstract][Full Text] [Related]
30. Current status and future prospects for satraplatin, an oral platinum analogue.
Choy H; Park C; Yao M
Clin Cancer Res; 2008 Mar; 14(6):1633-8. PubMed ID: 18347164
[TBL] [Abstract][Full Text] [Related]
31. Organo-platinum complexes as antitumor agents (review).
Hill JM; Speer RJ
Anticancer Res; 1982; 2(3):173-86. PubMed ID: 6751211
[TBL] [Abstract][Full Text] [Related]
32. Evolution of chemotherapy with platinum compounds.
Walker EM; Walker SM
Ann Clin Lab Sci; 1999; 29(4):263-74. PubMed ID: 10528825
[TBL] [Abstract][Full Text] [Related]
33. Clinical status of carboplatin.
Canetta R; Franks C; Smaldone L; Bragman K; Rozencweig M
Oncology (Williston Park); 1987 Jul; 1(5):61-70. PubMed ID: 3079484
[TBL] [Abstract][Full Text] [Related]
34. Platinum dose-intensity.
Los G
J Infus Chemother; 1996; 6(2):64-8. PubMed ID: 8809651
[TBL] [Abstract][Full Text] [Related]
35. Formation of platinum-DNA adducts in pediatric patients receiving carboplatin.
Tonda ME; Murry DJ; Rodman JH
Pharmacotherapy; 1996; 16(4):631-7. PubMed ID: 8840369
[TBL] [Abstract][Full Text] [Related]
36. Characterization and cellular uptake of platinum anticancer drugs encapsulated in apoferritin.
Xing R; Wang X; Zhang C; Zhang Y; Wang Q; Yang Z; Guo Z
J Inorg Biochem; 2009 Jul; 103(7):1039-44. PubMed ID: 19501911
[TBL] [Abstract][Full Text] [Related]
37. [Organoplatinum compounds. 1987 update].
Extra JM; Espie M; Calvo F; Marty M
Nouv Rev Fr Hematol (1978); 1988; 30(1-2):123-30. PubMed ID: 3290835
[TBL] [Abstract][Full Text] [Related]
38. Whither carboplatin? A replacement for or an alternative to cisplatin?
Gil A
J Clin Oncol; 1987 Dec; 5(12):2041-2. PubMed ID: 3316520
[No Abstract] [Full Text] [Related]
39. [Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention].
Montaguti M; Brandolini C; Ferri GG; Hatzopoulos S; Prete A; Pession A
Acta Otorhinolaryngol Ital; 2002 Feb; 22(1):14-8. PubMed ID: 12236007
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue.
Rahman A; Roh JK; Wolpert-DeFilippes MK; Goldin A; Venditti JM; Woolley PV
Cancer Res; 1988 Apr; 48(7):1745-52. PubMed ID: 3162402
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
